Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: GlaxoSmithKline Biologicals
Woman and Man Max 99 years
GlaxoSmithKline Biologicals
Update Il y a 4 ans
An open, phase IV, multicentre, study to assess the long-term persistence of antibodies against hepatitis B and the immune response to a hepatitis B vaccine challenge in healthy children aged 11-12 years, previously vaccinated with GlaxoSmithKline (GSK) Biologicals’ DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™) or GSK Biologicals’ DTPa-IPV/Hib and HBV (Engerix™- B) vaccines at the ages of 3, 5 and 11 months in clinical trial DTPa-HBV-IPV-031 (217744/031)
To assess the anti-HBs antibody response to a challenge dose of HBV vaccine in subjects aged 11-12 years, vaccinated in infancy with three doses of Infanrix hexa or Engerix-B at 3, 5 and 11 months of ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
GlaxoSmithKline Biologicals
Update Il y a 4 ans
An open, randomized, controlled, phase II study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals’ 11-valent pneumococcal conjugate vaccine, when administered intramuscularly as a 3, 5, 12 month vaccination schedule, as part of a staggered vaccination schedule
To assess the immune response post-dose 2 elicited by GSK Biologicals’ candidate 11Pn-PD-DiT vaccine administered according to a 3, 5, 12 month vaccination schedule as part of a staggered vaccination ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
GlaxoSmithKline Biologicals
Update Il y a 4 ans
A phase II, open-label, randomized, multicentre study to evaluate the feasibility of GSK Biologicals’ DTPa-IPV/Hib-MenC-TT vaccine co-administered with Prevenar compared with Pediacel co-administered with Menjugate and Prevenar, when given in healthy infants as a three-dose primary vaccination course at 2, 3 and 4 months of age and to evaluate Menitorix given to these children as a booster dose at 12 months of age
•To demonstrate that GSK Biologicals’ DTPa IPV/Hib-MenC-TT vaccine co-administered with Prevenar (MenC-Combo group) is non-inferior to Pediacel co-administered with Prevenar and Menjugate (Control gro...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
GlaxoSmithKline Biologicals
Update Il y a 4 ans
Long term immunogenicity and safety of GSK Biologicals’ Herpes Zoster vaccine 1437173A in healthy subjects Studie hodnotící dlouhodobou imunitní odpověď a bezpečnost očkovací látky proti pásovému oparu společnosti GSK Biologicals´u zdravých účastníků
To evaluate cell-mediated and humoral immune responses of the study vaccine in healthy elderly adults overall and within each age cohort (60-69 years of age [YOA] and ≥ 70 YOA) at Months 48, 60 and 72...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
GlaxoSmithKline Biologicals
Update Il y a 4 ans
Immunogenicity, safety and reactogenicity study of GSK Biologicals’ pneumococcal vaccine (Synflorix™) when administered to children who are at an increased risk of pneumococcal infection
To assess the immunogenicity of GSK Biologicals’ 10Pn-PD-DiT vaccine when administered to at-risk children aged between 2-17 years, either as a 2-dose catch-up vaccination in unprimed children or as a...
Country
None
organs
None
Specialty
None
More information
Woman and Man Max 99 years
GlaxoSmithKline Biologicals
Update Il y a 4 ans
A phase III, observer-blind, randomised study to evaluate the safety and immunogenicity of one and two administrations of pandemic monovalent (H5N1) influenza vaccine (split virus formulation containing 15 µg HA and adjuvanted with AS03) in adults aged 18 years and older
The primary objective is to evaluate the safety/reactogenicity of the pandemic influenza vaccine in terms of : •solicited local/general symptoms during 7 days post-vaccination, •unsolicited symptoms ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
GlaxoSmithKline Biologicals
Update Il y a 4 ans
A phase IV, open, multicentric study to evaluate the immune response to a hepatitis B challenge dose in healthy subjects, 72 to 78 months after they received a primary vaccination course of GSK Biologicals’ Engerix™-B (thiomersal-free 20 µg or preservative-free 10 µg) vaccine, in the primary study HBV-280
To assess the immune response to a challenge dose of hepatitis B vaccine administered in subjects who previously received a complete hepatitis B primary vaccination course, 72 to 78 months ago.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
GlaxoSmithKline Biologicals
Update Il y a 4 ans
Immunogenicity and safety study of GSK Biologicals’ Herpes Zoster vaccine GSK1437173A when co-administered with GSK Biologicals’ seasonal influenza vaccine GSK2321138A in adults aged 50 years and older
To evaluate the vaccine response rate (VRR) to the HZ/su vaccine (based on the humoral immune response) one month after the last vaccine dose in the HZ/su-FLU-D-QIV co-administration group. To dem...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
GlaxoSmithKline Biologicals
Update Il y a 4 ans
Long term follow up (LTFU) study 16-20 yrs after hepatitis B vaccination in newborns of mothers who were seropositive for Hepatitis B envelope antigen (HBeAg) and Hepatitis B surface antigen (HBsAg)
To evaluate the anti-HBs persistence up to Year 20 after the first vaccine dose of the primary vaccination. To evaluate the prevalence and incidence of other Hepatitis B markers (HBsAg, anti-bodies t...
Country
None
organs
None
Specialty
None
More information
Woman and Man Max 99 years
GlaxoSmithKline Biologicals
Update Il y a 4 ans
A dose ranging safety and immunogenicity study of GlaxoSmithKline (GSK) Biologicals’ GSK1557484A vaccine in children 6 to less than 36 months of age
Primary Doses • To assess the performance of alternative dosing regimens for primary immunization with Q-Pan H5N1 vaccine using an immunogenicity-fever index that considers: - immunogenicity by Hemagg...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next